Repairon BioVAT–HF: Key Interim Results (AHA 2025)
Repairon BioVAT–HF: Key Interim Results (AHA 2025)
Source: (AHA) Scientific Sessions, Nov 10, 2025
Key notes :
1. Study Design
• First-in-patient Phase 1–2 trial (BIOVAT-HF-DZHK20).
• Human iPSC-derived engineered heart muscle (EHM) patches transplanted onto the LV of patients with advanced HFrEF.
• Open-label; dose escalation followed by treatment of 16 patients at maximal safe dose.
2. Safety Outcomes
• Well tolerated with no unexpected safety signals.
• Acceptable rates of MACE, arrhythmias, and immune rejection.
3. 3-Month Efficacy (Interim)
• Heart wall thickness ↑ 4.5 mm
• LVEF ↑ 3.9%
• KCCQ-23 Overall Summary Score ↑ 6.7 points
4. Long-Term Follow-Up (up to 36 months)
• Sustained wall thickness gain: +2.7 mm
• LVEF improvement: +6.9%
• Quality of life improvement: +17 points
5. Clinical Significance
• Demonstrates biological ventricular assist tissue (BioVAT) can augment myocardial structure and function.
• Potential new option for patients refractory to guideline-directed therapies.
6. Supporting Evidence
• Builds on decades of research including:
• Preclinical data in Rhesus macaques
• First-in-human cardiac remuscularization published in Nature (Jebran et al., 2025)
7. Next Steps
• Transition toward pivotal Phase III trial.
• Expansion of clinical sites in and outside Germany.
8. Unmet Clinical Need
• Advanced HF: high mortality (≈50% within 1 year).
• Current options limited to LVADs or heart transplantation.
9. About Repairon GmbH
• Germany-based biotech (founded 2014).
• Specializes in reparative engineered heart muscle therapies.
